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We report the clinical out-
comes in men treated with
image guided proton therapy
for localized prostate cancer.
In this cohort of 1327 men
with a median follow-up
time of 5.5 years, proton
therapy provided excellent
biochemical control rates for
patients with low-risk, inter-
mediate-risk, and high-risk
prostate cancer. Proton ther-
apy also preserves patient-
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associated with a lowReprint requests to: Curtis Bryant, MD, MP
2015 North Jefferson St, Jacksonville, FL
1800; E-mail: cbryant@floridaproton.org
C. Bryant and T. L. Smith share first author
Conflict of interest: none.
Int J Radiation Oncol Biol Phys, Vol. 95, No. 1
0360-3016/ 2016 The Authors. Published by
licenses/by-nc-nd/4.0/).
http://dx.doi.org/10.1016/j.ijrobp.2016.02.038Purpose: To report clinical outcomes in patients treated with image guided proton
therapy (PT) for localized prostate cancer.
Methods and Materials: The medical records of 1327 men were reviewed. Each man
was enrolled on an outcomes tracking study. Dual enrollment on a prospective clinical
trial was allowed. Each patient was treated for localized prostate cancer with PT at our
institution between 2006 and 2010. Ninety-eight percent of patients received
78 Gy (radiobiological equivalent [RBE]) or higher; 18% received androgen depriva-
tion therapy (ADT). The 5-year freedom from biochemical progression (FFBP),
distant metastasis-free survival, and cause-specific survival rates are reported for each
risk group. Data on patient-reported quality of life and high-grade toxicities were pro-
spectively collected and reported. A multivariate analysis was performed to identify
clinical predictors of biochemical failure and urologic toxicity.
Results: The median follow-up time was 5.5 years. The 5-year FFBP rates were 99%,
94%, and 74% in low-risk, intermediate-risk, and high-risk patients, respectively. The
actuarial 5-year rates of late grade 3þ Common Terminology Criteria for Adverse
Events, version 4.0, gastrointestinal (GI) and genitourinary (GU) toxicity were 0.6%
and 2.9%, respectively. Multivariate analysis showed a significant correlation betweenH, University of Florida,
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logic toxicity.grade 3þ GU toxicity and pretreatment prostate reductive procedures (P<.0001), pros-
tate volume (PZ.0085), pretreatment a-blockers (PZ.0067), diabetes (PZ.0195),
and doseevolume histogram parameters (PZ.0208). The median International Pros-
tate Symptom Scores pretreatment scores and scores at 5 years after treatment were
7 and 7, respectively. The mean Expanded Prostate Cancer Index Composite (EPIC)
scores significantly declined for sexual summary for patients not receiving ADT (from
67 to 53) between baseline and 5 years.
Conclusions: Image guided PT provided excellent biochemical control rates for patients
with localized prostate cancer. The actuarial rates of high-grade toxicity were low after
PT. From pretreatment to 5 years of follow-up, a significant decline was found only in
mean EPIC sexual summary scores. Prospective clinical studies are needed to determine
the comparative effectiveness of PTand other radiation treatment strategies. 2016 The
Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
More than 230,000 men received diagnoses of prostate
cancer in 2014, making it the most common noncutaneous
cancer among men in the United States (1). Numerous
treatment strategies exist for managing localized prostate
cancer, including external beam radiation therapy, brachy-
therapy, radical prostatectomy, and cryotherapy (2). Each
strategy differs in cost, treatment efficacy, and side effect
profile, making treatment decisions difficult. Furthermore,
technological innovation improves each strategy over time,
adding complexity to comparative effectiveness studies.
One such innovation within the category of external beam
radiation therapy is proton therapy (PT). Although intensity
modulated radiation therapy (IMRT) allows for the delivery of
high-dose photon-based external beam radiation therapy with
relative safety, PT provides an improvement over IMRT by
reducing the radiation dose tonormal tissue outside thevolume
targeted for cancer treatment. PT delivers less dose to normal
tissues surrounding the prostate, like the rectum and bladder,
comparedwith photon radiation (3-5),whichmay result in less
toxicity and improved quality of life (QOL). To date, only a
few studies have been published documenting the clinical
outcomes in patients treated with PT for prostate cancer with
more than 5 years of follow-up (6, 7), so the relative effec-
tiveness of PT compared with other strategies is unknown (8).
Recently, we reported encouraging 5-year outcomes
from 3 prospective trials in patients treated for localized
prostate cancer with PT at our institution (7). The purpose
of the present study was to update those findings, include
them with a larger population of unselected consecutive
patients, and identify factors predictive of either biochem-
ical failure or urologic toxicity.
Methods and Materials
Patients
This study was approved by our institutional review board
and was based on a review of the medical records of 1538men with biopsy-proven localized prostate cancer treated
consecutively with PT at our institution between 2006 and
2010 on a prospective outcome tracking protocol (OTP).
The patients could also be dual enrolled on clinical trials.
During the early part of the study, 3 prospective clinical
trials designed to establish benchmark outcomes with PT
delivered with standard dose and fractionation accrued pa-
tients with localized prostate cancer (7, 9). The first trial,
PR01, included low-risk prostate cancer patients treated
with PT to 74 to 78 Gy(radiobiological equivalent [RBE]) at
2 Gy(RBE) per fraction (nZ89). The second was a dose-
escalation trial, PR02, which included patients with
intermediate-risk prostate cancer who were treated to 74 to
82 Gy(RBE) of PT at 2 Gy(RBE) per fraction (nZ81). The
third prospective trial, PR03, included high-risk prostate
cancer patients treated with PT to 74 to 78 Gy(RBE) at
2 Gy(RBE) per fraction to the prostate and proximal seminal
vesicles with concurrent weekly docetaxel (20 mg/m2)
without pelvic node irradiation, followed by androgen
deprivation therapy (ADT) for 6 months (nZ39). In total,
209 patients accrued in 2006 and 2007 were dually enrolled
on the early benchmark trials and the general OTP and were
included in this study. Patients were excluded from this
analysis if they had nodal metastasis present before treat-
ment (nZ13), prior local treatment for prostate cancer
(nZ14), did not complete PT (nZ5), refused, were ineli-
gible for or withdrew from the outcomes tracking protocol
(nZ19), or if no clinical follow-up information was avail-
able (nZ11). Later during the timeframe of this study
(2008-2010), other clinical trials were conducted involving
hypofractionation in low-risk and intermediate-risk patients
(nZ141) and pelvic node irradiation and concurrent
chemotherapy (nZ8) in high-risk patients; because the
focus of the current study was to report overall outcomes of
standard fractionation PT, these patients were not included
in the current analysis. A total of 1327 patients were
included in this study, and biochemical, clinical, and QOL
data were collected prospectively from each patient at reg-
ular intervals. For the analysis of the 2 endpoints of freedom
from disease progression and toxicity after PT, other specific
exclusions were made. In the toxicity analysis, 34 patients
Bryant et al. International Journal of Radiation Oncology  Biology  Physics424who received IMRT for elective nodal irradiation and 4
patients who did not have any gastrointestinal (GI) or
genitourinary toxicity (GU) follow-up information were
excluded, leaving a total of 1289 patients (Table 1). In the
biochemical disease control analysis, because the focus was
on tumor control after PT, patients who received concurrent
chemotherapy (nZ53) and patients with less than 2 years of
biochemical follow-up for reasons other than death (nZ60)
were also excluded, leaving 1214 patients for the
biochemical disease control analysis (Table 1).
The pretreatment workup for all patients included med-
ical history, digital rectal examination, and in-house pa-
thology review of prostate biopsy specimens to verify the
diagnosis and Gleason score. The workup also included
prostate-specific antigen (PSA), 1.5-Tesla to 3.0-Tesla
magnetic resonance prostate imaging (MRI) and computed
tomography (CT) scans of the pelvis, and bone scans in
patients with intermediate-risk and high-risk disease.
The patients’ histories were reviewed, and potential risk
factors for treatment failure and toxicity were recorded,
including maximum PSA, clinical stage, the results of
pretreatment staging studies, prostate size per transrectal
ultrasonographic findings at the time of fiducial marker
placement, maximum Gleason score, maximum percentage
of involvement in any biopsy core, percentage of zones
involved on prostate biopsy, and the use of ADT. A 10-zone
or more prostate biopsy was recommended within 6 months
of beginning PT. The patient characteristics for this cohort
are listed in Table 1.
Treatment simulation, planning, and delivery
The treatment planning procedures have also been previously
described (9). The clinical target volume (CTV) for low-risk
patients included only the prostate as visualized on fused
MRI and CT images; the CTV in intermediate-risk and high-
risk patients also included the proximal 2 cm of seminal
vesicles. In the OTP population, reduction off of the seminal
vesicles was allowed in patients with intermediate-risk dis-
ease. For high-risk patients with a risk for pelvic node
involvement >15%, IMRTwas delivered to the initial CTV,
which included the pelvic nodes, the proximal seminal ves-
icles, and the prostate. The CTV was expanded by 5 mm
axially and 8 mm in the superior and inferior axes to create a
planning target volume (PTV); in 2008, the parameters for
PTVexpansionwere reduced to 4mmaxially and 6mm in the
superior and inferior axes as the result of an internal intra-
fraction motion analysis. Lateral or oblique fields were used
with PT. The edge of the brass aperture was placed 1 cm
beyond the PTV in the superior, inferior, and anterior di-
rections and 7 mm in the posterior direction. Treatment was
planned with an Eclipse system (Varian Medical Systems,
Palo Alto, CA) using a CT Hounsfield conversion algorithm
(10). Distal and proximal range uncertainty margins of 5 mm
and a smearing value of 19 mm were used.
The treatment planning guidelines included goals for
both target coverage and dose constraints for organs at risk(OARs), including the bladder, bladder wall, rectum, rectal
wall, and femoral heads. For target coverage, 95% of the
PTV received 100% of the prescribed dose, and 100% of
the PTV received at least 95% of the prescribed dose.
Minor adjustments were allowed when dose constraint
goals to the OARs could not be met, including a reduction
in total dose, a reduction in dose per fraction, and treatment
of both rather than only 1 field per day. In total, 1311 (99%)
patients were treated with 2-Gy(RBE) fractions. The dose
to the PTV was 78 to 80 Gy(RBE) in 1141 (86%) patients
and 81 to 82 Gy(RBE) in 161 (12%) patients. Failure to
meet the dose constraints to OARs, issues relating to patient
preference, or both resulted in 24 patients (1.8%) receiving
73.8 to 77.4 Gy(RBE) in 1.8- to 2.0-Gy(RBE) daily doses.
One patient discontinued treatment after 72 Gy(RBE) over
36 fractions. All patients treated with 1.8-Gy(RBE) frac-
tions had both fields treated each day, and 1 patient was
treated in the prone position in an effort to improve the
daily dose distribution. Thus, 1324 patients (99.0%)
received 75 Gy(RBE), and 1302 (98%) received
78 Gy(RBE).
Androgen deprivation therapy was primarily recom-
mended for patients with high-risk prostate cancer for a
duration of 6 to 24 months. Most ADT prescriptions for
patients with low-risk or intermediate-risk disease had been
prescribed by outside physicians before consultation for PT.
Two hundred forty-four patients (18%) received neo-
adjuvant, concurrent, or adjuvant hormone therapy. The
treatment characteristics for the patient cohort are listed in
Table 1.
Follow-up and observed outcome
Follow-up included medical history review and physical
examinations at 6-month intervals after treatment. PSA
tests were performed every 3 months for 3 years and then
semianually. Biochemical failure was determined according
to the Phoenix definition (nadir þ 2 ng/mL) (11). The time
to reported biochemical outcomes was calculated from the
radiation start date. Clinical failure (local, regional, or
distant) was based on available clinical, histologic, or
radiographic evidence of disease recurrence. In the event of
biochemical failure, patients underwent bone scans, pelvic
MRI, and occasionally positron emission tomographyeCT.
Biopsy of the prostate was not performed unless the results
of pelvic MRI or digital rectal examination suggested
possible local disease progression.
The patients were seen at 6-month intervals after treat-
ment to prospectively assess toxicity according to the
Common Terminology Criteria for Adverse Events, version
3.0 (CTCAEv3) (12). The patients also prospectively
completed International Prostate Symptom Score (IPSS)
and QOL assessments (Expanded Prostate Cancer Index
Composite; EPIC) at 6-month intervals after treatment for
5 years, then annually thereafter. The EPIC summary and
subscales were calculated and reported using a scale of 0 to
100, with higher scores indicating better outcomes.
Table 1 Patient and treatment characteristics (NZ1327)
Characteristics No. of patients
Biochemical and clinical freedom
from progression analysis Urologic toxicity analysis
Excluded Included Excluded Included
Total number of patients 1327 113 1214 38 1289
Median age, y (range) 66 (41-88) 68 (41-84) 66 (42-88) 70 (50-87) 66 (41-88)
Race and ethnicity
African-American 85 (6%) 12 (11%) 73 (6%) 4 (10%) 81 (6%)
Asian-Pacific 12 (1%) 0 (0%) 12 (1%) 0 (0%) 12 (1%)
Hispanic 23 (2%) 0 (0%) 23 (2%) 1 (3%) 22 (2%)
White 1207 (91%) 101 (89%) 1106 (91%) 33 (87%) 1174 (91%)
T stage*
TX 1 (<1%) 0 (0%) 1 (<1%) 0 (0%) 1 (<1%)
T1 953 (72%) 75 (66%) 878 (72%) 14 (37%) 939 (73%)
T2a 229 (17%) 14 (12%) 215 (18%) 3 (8%) 226 (17%)
T2b 90 (7%) 12 (11%) 78 (6%) 10 (26%) 80 (6%)
T2c 34 (3%) 6 (5%) 28 (2%) 2 (5%) 32 (2%)
T3 20 (2%) 6 (5%) 14 (1%) 9 (24%) 11 (1%)
Gleason score
6 643 (48%) 40 (35%) 603 (50%) 5 (13%) 638 (50%)
7 Z 3 þ 4 332 (25%) 17 (15%) 315 (26%) 5 (13%) 327 (25%)
7 Z 4 þ 3 161 (12%) 8 (7%) 153 (13%) 2 (5%) 159 (12%)
8 122 (9%) 30 (27%) 92 (8%) 11 (29%) 111 (9%)
9-10 69 (5%) 18 (16%) 51 (4%) 15 (40%) 54 (4%)
PSA
Median (range) 6 (0.3-134) 6.4 (0.5-90.4) 6 (0.3-134) 14.6 (4.3-58.6) 6.0 (0.3-134)
<10 1090 (82%) 77 (68%) 1013 (83%) 11 (29%) 1079 (84%)
10 to <20 183 (14%) 16 (14%) 167 (14%) 11 (29%) 172 (13%)
20 54 (4%) 20 (18%) 34 (3%) 16 (42%) 38 (3%)
Risk category
Low 547 (41%) 33 (29%) 514 (42%) 3 (8%) 544 (42%)
Intermediate 551 (42%) 19 (17%) 532 (44%) 1 (3%) 550 (43%)
High 229 (17%) 61 (54%) 168 (14%) 34 (89%) 195 (15%)
Maximum percentage
core involvement
Unknown 41 3 38 3 38
<50% 844 (66%) 61 (55%) 783 (67%) 9 (26%) 835 (67%)
50% 442 (34%) 49 (45%) 393 (33%) 26 (74%) 416 (33%)
Percentage of prostate zones
positive on biopsy
Unknown 7 2 5 0 7
<50% 889 (67%) 66 (59%) 823 (68%) 9 (24%) 880 (69%)
50% 431 (33%) 45 (41%) 386 (32%) 29 (76%) 402 (31%)
Perineural invasion
Yes 251 (19%) 31 (27%) 220 (18%) 18 (46%) 233 (18%)
Dose
<75 Gy(RBE) 3 (<1%) 2 (2%) 1 (<1%) 1 (3%) 2 (<1%)
75-77 Gy(RBE) 22 (2%) 0 (0%) 22 (2%) 10 (26%) 12 (1%)
78-80 Gy(RBE) 1141 (86%) 104 (92%) 1037 (85%) 26 (68%) 1115 (87%)
81-82 Gy(RBE) 161 (12%) 7 (6%) 154 (13%) 1 (3%) 160 (12%)
Elective pelvic node radiation
Yes 34 (3%) 0 (0%) 34 (3%) 34 (89%) 0 (0%)
Elective radiation to
seminal vesicles
Yes 743 (56%) 77 (68%) 666 (55%) 35 (92%) 708 (55%)
Concurrent chemotherapy 49 (4%) 49 (43%) 0 (0%) 0 (0%) 49 (4%)
Androgen deprivation therapy 244/1327 (18%) 59/113 (52%) 185/1214 (15%) 25/38 (66%) 219/1289 (17%)
Low risk 37/547 (7%) 1/33 (3%) 36/514 (7%) 0/3 (0%) 37/544 (7%)
Intermediate risk 56/551 (10%) 3/19 (16%) 53/532 (10%) 1/1 (100%) 55/550 (10%)
(continued on next page)
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Table 1 (continued )
Characteristics No. of patients
Biochemical and clinical freedom
from progression analysis Urologic toxicity analysis
Excluded Included Excluded Included
High risk 151/229 (66%) 55/61 (90%) 96/168 (57%) 24/34 (71%) 127/195 (65%)
Comorbidities
Diabetes 175 (13%) 18 (16%) 157 (13%) 6 (16%) 169 (13%)
No diabetes 1152 (87%) 95 (84%) 1057 (87%) 32 (84%) 1120 (87%)
Aspirin 491 (37%) 42 (37%) 449 (37%) 11 (29%) 480 (37%)
No aspirin 836 (63%) 71 (63%) 765 (63%) 27 (71%) 809 (63%)
Prescription anticoagulant 121 (9%) 14 (12%) 107 (9%) 2 (5%) 119 (13%)
No prescription anticoagulant 1206 (91%) 99 (88%) 1107 (91%) 36 (95%) 1170 (87%)
Pretreatment urologic function
Pretreatment a-blockers 252 (19%) 26 (23%) 226 (19%) 6 (16%) 246 (19%)
No pretreatment a-blockers 1075 (81%) 87 (77%) 988 (81%) 32 (84%) 1043 (81%)
Pretreatment a-reductase
inhibitors
102 (8%) 9 (8%) 93 (8%) 1 (3%) 101 (8%)
No pretreatment a-reductase
inhibitors
1225 (92%) 104 (92%) 1121 (92%) 37 (97%) 1188 (92%)
Pretreatment TURPy 96 (7%) 14 (12%) 82 (7%) 0 (0%) 96 (7%)
No pretreatment TURPy
or unknown
1231 (93%) 99 (88%) 1132 (93%) 38 (100%) 1193 (93%)
International Prostate
Symptom Score
Not available 28 3 25 2 26
<15 1060 (82%) 83 (75%) 977 (82%) 27 (75%) 1033 (82%)
15 239 (18%) 27 (25%) 212 (18%) 9 (25%) 230 (18%)
Prostate volume
Not available 5 2 3 1 4
<Median (36 cm3) 649 (49%) 66 (59%) 583 (48%) 19 (51%) 630 (49%)
Median (36 cm3) 673 (51%) 45 (41%) 628 (52%) 18 (49%) 655 (51%)
<40 cm3 777 (59%) 74 (67%) 703 (58%) 27 (73%) 750 (58%)
40-59 cm3 355 (27%) 19 (17%) 336 (28%) 8 (22%) 347 (27%)
60 cc 190 (14%) 18 (16%) 172 (14%) 2 (5%) 188 (15%)
Follow-up, y
PSA median (range) 5.1 (0.1-8.8) 1.9 (0.1-8.2) 5.3 (0.3-8.3) 3.9 (0.5-7.0) 5.2 (0.1-8.8)
Toxicity median (range) 5.5 (0.5-8.8) 5.5 (0.7-8.4) 5.5 (0.5-8.8) 4.7 (0.5-7.0) 5.5 (0.6-8.8)
Abbreviation: TURP Z transurethral resection of the prostate.
* T stage missing in 1 patient because prior colectomy precluded digital rectal examination.
y Includes all prostate reductive procedures.
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“late,” and those occurring during treatment or <6 months
after PT were scored as “acute.” CTCAE, version 4.0
(CTCAEv4) (13) was published in 2009; all patients with
CTCAEv3 grade 3 toxicities were also retrospectively
categorized according to CTCAEv4 criteria.
Grade 3 urologic toxicity included the following: urinary
frequency or urgency resulting in urination 1 time per
hour or necessitating a catheter; urinary retention requiring
more than daily catheterization or surgical intervention such
as transurethral resection of the prostate (TURP), transure-
thral needle ablation, or indwelling suprapubic catheter;
hematuria requiring blood transfusion(s); hyperbaric oxygen
(HBO) treatment; or a surgical intervention such as a
cystoscopy with a procedure (either a biopsy specimen
showing necrosis or cauterization). Cystoscopies revealing
normal bladder and not requiring an intervention (such as
biopsy, cautery, or resection) were not scored as a grade 3toxicity. Specific GI symptoms evaluated included diarrhea,
proctitis, abdominal cramping, fecal incontinence, and
rectal bleeding; a detailed analysis of factors associated with
GI toxicity has been reported (14).Statistical analysis
Statistical analyses were performed with SAS and JMP
software (SAS Institute, Cary, NC). The Kaplan-Meier
product-limit method provided estimates of freedom from
biochemical recurrence, death of disease, and death of any
cause. For each of these outcomes, the log-rank test statistic
was used in a series of univariate analyses to assess the
level of statistical significance between strata of selected
prognostic factors. Proportional hazards regression with
backward selection was then used for multivariate analysis.
A P value of <.05 was considered statistically significant.
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Fig. 1. Freedom from biochemical failure by risk group.
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mate freedom from grade 3þ GU toxicity; the log-rank test
statistic was used to assess statistical significance of these
estimates after stratification by selected prognostic factors.
Multivariate analysis of these same prognostic factors was
performed with proportional hazards regression; a back-
ward selection procedure was added to assure the most
parsimonious final model for each toxicity endpoint. The
most optimal breakpoints for each of a series of dosimetric
parameters were determined with recursive partitioning
before the multivariate analysis. Each dosimetric parameter
was then reformatted as a binary variable based on the
optimal breakpoint. Two-sided P values of .05 were
considered statistically significant. For EPIC patient-
reported QOL comparisons, the mean and median scores
are reported. The mean score change between baseline
values and 5-year values was calculated, and significant
differences were reported using the minimally important
difference technique published by Skolarus et al for the
EPIC composite short form (15).Results
Disease control
The median follow-up time for biochemical outcomes was
5.3 years (range, 0.3-8.3 years). The median time to PSA
nadir was 3.6 years (range, 0.3-8.4 years), and the median
PSA nadir was 0.2 ng/mL for all patients. The median PSA
nadir was 0.3 ng/mL for patients who did not receive ADT.
By risk group, the median PSA nadir was 0.3 ng/mL for
low-risk, 0.2 ng/mL for intermediate-risk, and 0.1 ng/mLfor high-risk patients. The median times to nadir by risk
group were 4.2, 3.6, and 1.1 years, respectively. For patients
who did not receive ADT, the median PSA nadir by risk
group was 0.3 ng/mL for low-risk, 0.2 ng/mL for
intermediate-risk, and 0.3 ng/ml for high-risk patients. The
median times to nadir by risk group for patients who did not
receive ADT were 4.2, 3.6, and 2.2 years, respectively. At
last follow-up, the median PSA was 0.3 ng/mL (range, 0-
800 ng/mL) for all patients. It was 0.2 ng/mL (range, 0.01-
100 ng/mL) for patients who received ADT and 0.3 ng/mL
(range, 0-800 ng/mL) for patients who did not receive ADT.
Biochemical failure occurred in 94 patients (7.7%) at a
median of 3.3 years (range, 0.3-7.1 years). The 5-year
freedom from biochemical progression (FFBP) rates were
99% for low-risk, 94% for intermediate-risk, and 74% for
high-risk patients (Fig. 1).
Patterns of failure
All patients with disease progression had biochemical
progression. PSA progression was the sole indication of
disease progression in 42 patients (3.5%) but was
accompanied by isolated biopsy-proven local failure in 6
patients (0.5%), isolated pelvic nodal failure in 10 pa-
tients (0.8%), isolated distant metastases in 24 patients
(2.0%), or a combination of clinical sites in 12 patients
(1.0%), including local (nZ5), nodal (nZ7), and/or
distant metastasis (nZ11). Freedom from distant metas-
tasis at 5 years was 99% for low-risk, 99% for
intermediate-risk, and 98% for high-risk patients. The
median times to distant metastasis for each risk group
were 3.6, 4.0, and 3.0 years, respectively. Freedom from
nodal metastasis at 5 years was 99% for low-risk, 99% for
Table 2 Univariate and multivariate analysis for biochemical failure at 5 years
Factors
Univariate Multivariate
5-year FFBP P value Hazard ratio (CI) P value
Risk group
Low 99% <.01 - -
Intermediate 94% -
High 75% -
Clinical T stage (T1-2 vs T3) 94% vs 42% <.01 0.9 (0.3-2.6) .81
Gleason score
4-7 96% <.01 - .02
8 85% 1.7 (0.9-3.2)
9 55% 4.2 (2.4-7.4)
Percentage of zones undergoing biopsy and positive
for cancer (<50% vs  50%)
97% vs 86% <.01 1.8 (1.1-2.9) .02
Maximum percentage of tumor involvement in each
core (<50% vs  50%)
97% vs 89% <.01 1.0 (0.6-21.6) .81
Prostate-specific antigen (ng/mL)
<10 96% <.01 - .02
10 to <20 87% 1.5 (0.9-2.5)
20 58% 3.8 (2.0-7.3)
Perineural invasion (yes vs no) 83% vs 96% <.01 1.8 (1.2-2.9) .01
Elective seminal vesicle radiation (yes vs no) 99% vs 89% <.01 0.2 (0.1-0.5) <.01
Receipt of androgen deprivation therapy (yes vs no) 84% vs 95% <.01 0.9 (0.5-1.6) .80
Elective pelvic nodal radiation therapy (yes vs no) 52% vs 94% <.01 0.9 (0.4-2.2) .98
Abbreviations: CI Z confidence interval; FFBP Z freedom from biochemical progression.
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median times to nodal metastasis were 4.4, 2.8, and
2.0 years, respectively.
Survival
Fifty-five deaths occurred, including 14 from intercurrent
disease and 41 from prostate cancer. The 5-year rates of
prostate cancerespecific survival and overall survival were
97% and 96%, respectively. Cause-specific survival rates at
5 years were 98% for low-risk, 97% for intermediate-risk,
and 95% for high-risk patients.
Predictors of biochemical failure
The results from the univariate and multivariate analyses
of factors potentially predictive of 5-year FFBP are shown
in Table 2. On multivariate analysis, Gleason score (4-7 vs
8 vs  9-10; PZ.02), PSA (0 to <10 vs10 to <20 vs 20;
PZ.02), perineural invasion (yes vs no; PZ.01), and the
percentage of positive zones on biopsy (<50% vs 50;
PZ.02) were significant predictors of biochemical failure.
Seventy-eight percent (nZ415) of intermediate-risk pa-
tients had only 1 intermediate risk factor (Gleason 7, PSA
10 to <20, or clinical stage T2b-c), and 22% (nZ117) had
2 or more. Patients with 2 or more intermediate risk
factors had a lower rate of FFBP than did patients with
only 1 intermediate risk factor (90% vs 95%, PZ.03).
Similarly, those 19 (12%) high-risk patients with 2 or
more high-risk factors (Gleason 8-10, PSA 20, or clin-
ical stage T3-4) had a lower rate of FFBP compared with149 patients (88%) with only 1 high-risk factor (32% vs
80%, P<.01). Patients with high-risk disease based solely
on Gleason 8 histology (nZ85) had a biochemical
relapse-free survival rate of 87.5% at 5 years.
Toxicity
Seventy of the 1289 patients (5.4%) had at least 1 episode
of a CTCAEv3 grade 3þ GU toxicity, including 9 patients
with only acute events, 58 with only late events, and 3 with
both acute and late events. One of the 70 events was scored
as grade 4; there were no grade 5 events.
Eight of the 12 patients (67%) with acute grade 3 events
had urinary obstructive symptoms requiring temporary
catheterization. Three patients had bladder irritation treated
with catheterization (nZ2) and HBO (nZ1); and 1 patient
with hematuria required a blood transfusion. In 5 of the 12
cases, subsequent additional acute or late grade 3 in-
terventions were required: 3 patients required temporary
catheters for urinary obstruction, 1 patient required 2 TURP
procedures 2.1 and 4.8 years after PT, and a fifth patient
underwent 2 TURPs 2.7 and 2.9 years after PT and later
experienced hematuria that was treated with cauterization
and HBO.
Forty-nine (80%) of the 61 patients (4.7%) with late
CTCAEv3 grade 3þ events experienced only 1 event,
predominantly related to obstructive symptoms in 26, he-
maturia in 18, and irritative symptoms in 5 patients. Twelve
(20%) patients had more than 1 late grade 3 event: 3 had
only obstructive symptoms, 1 had only hematuria, and the
remaining 8 had a combination of obstructive symptoms,
Table 3 Univariate and multivariate analyses of clinical and treatment factors potentially associated with late grade 3þ GU toxicities
Characteristics
All patients with grade 3þ GU toxicity
Patients with grade 3þ GU toxicities without
pretreatment TURP*
Univariate Multivariate Univariate Multivariate
P-value HR (CI) P-value HR (CI) P-value HR (CI) P-value HR (CI)
Factors and co-morbidities
Age (<60 vs 60) .4437 0.8 (0.4-1.4) NT - .8298 1.1 (0.5-2.1) NT -
Race (Non-African
American vs African
American)
.5341 0.6 (0.3-1.9) NT - .6617 0.8 (0.3-3.4) NT -
Diabetes (no vs yes) .0210 0.5 (0.3-0.9) .0195 0.5 (0.3-0.9) .0447 0.5 (0.3-1.1) .0322 0.5 (0.2-0.9)
Aspirin (no vs yes) .5369 0.9 (0.5-1.4) NT - .7607 0.9 (0.5-1.7) NT -
Prescription anticoagulants
(no vs yes)
.0316 0.5 (0.3-1.0) .1848 0.6 (0.3-1.2) .1992 0.6 (0.3-1.5) .3685 0.6 (0.3-1.6)
Prostate factors
Prostate volume Median Z
36.3 cc (<36.3 vs 36.3)
.1734 0.7 (0.4-1.2) NT - .3857 0.8 (0.4-1.4) NT -
Prostate volume (<40 vs
40-60 vs >60 cc)
<40 vs >60 <.0001 0.3 (0.2-0.5) .0085 0.4 (0.2-0.8) .0001 0.3 (0.2-0.6) .0268 0.5 (0.3-1.1)
40-60 vs >60 0.3 (0.1-0.5) 0.4 (0.2-0.8) 0.2 (0.1-0.6) 0.3 (0.1-0.7)
Disease factors
T stage (T1 vs T2+) .8241 1.1 (0.6-2.0) NT - .9692 1.0 (0.5-2.0) NT -
T stage (T1-T2a vs T2b+) .5614 1.4 (0.6-4.5) NT - .4293 1.8 (0.5-10.8) NT -
Maximum Gleason score
(4-6 vs 7 vs 8-10)
.8241 1.1 (0.6-2.0) NT - .9692 1.0 (0.5-2.0) NT -
4-6 vs 8-10 .6477 0.8 (0.4-1.8) NT - .4099 0.7 (0.3-1.8) NT -
7 vs 8-10 0.7 (0.3-1.6) - - 0.5 (0.2-1.4) - -
Risk group (low vs
intermediate vs high)
Low vs high .844 0.9 (0.4-1.9) NT - .4567 0.8 (0.4-1.9) NT -
Intermediate vs high - 0.8 (0.4-1.8) - - - 0.6 (0.3-1.5) - -
Pretreatment GU function
a-blockers <.0001 0.4 (0.2-0.6) .0067 0.5 (0.3-0.8) <.0001 0.3 (0.2-0.6) .0008 0.3 (0.2-0.6)
a-reductase inhibitors .1385 0.6 (0.3-1.3) .89 1.0 (0.4-2.1) .7361 0.8 (0.3-2.8) .7302 1.3 (0.4-3.7)
Pretreatment TURP* <.0001 0.2 (0.1-0.3) <.0001 0.2 (0.1-0.3) N/A - N/A -
Any pretreatment GU
symptom managementy
<.0001 0.3 (0.2-0.4) NT - .0019 0.4 (0.2-0.7) NT -
International Prostate
Symptom Score
.1219 0.6 (0.3-1.0) .4341 0.7 (0.4-1.3) .0325 0.5 (0.3-1.0) .3828 0.7 (0.4-1.4)
Treatment factors
Hormone therapy .0243 1.9 (1.0-3.2) NT - .1048 1.7 (0.8-3.4) NT -
Chemotherapy .6001 0.8 (0.3-2.5) NT - .554 0.7 (0.3-2.9) NT -
Prescribed dose (<79 CGE
vs 79 CGE)
.2208 1.6 (0.8-3.6) NT - .1744 1.9 (0.8-5.5) NT -
Organs-at-risk dose-volume
histogram factors
Absolute bladder volume
(cm3)
V30 <.0001 0.4 (0.2-0.6) .0208 0.5 (0.3-0.9) .0003 0.3 (0.2-0.6) .0224 0.5 (0.2-0.9)
V39 .0022 0.5 (0.3-0.8) .4029 0.8 (0.3-2.0) .0148 0.5 (0.3-0.9) .7378 1.0 (0.3-3.1)
V70 <.0001 0.4 (0.2-0.6) .5139 0.8 (0.3-2.6) .0004 0.4 (0.2-0.7) .8468 1.0 (0.3-4.1)
V75 .0012 0.4 (0.2-0.7) .4164 1.6 (0.4-5.7) .0018 0.4 (0.2-0.7) .8872 0.8 (0.2-3.3)
V80 .0077 0.5 (0.3-0.8) NT - .0321 0.5 (0.3-0.9) NT -
V82 .1339 1.6 (0.9-3.3) NT - .1063 1.9 (0.9-4.7) NT -
Absolute bladder wall
volume (cm3)
V30 <.0001 0.3 (0.2-0.5) .8871 1.3 (0.1-20.3) .0008 0.3 (0.2-0.7) .9108 1.3 (0.1-29.4)
V39 <.0001 0.3 (0.2-0.5) .4614 0.5 (0.0-9.3) .0007 0.3 (0.2-0.7) .6192 0.7 (0.0-18.0)
(continued on next page)
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Table 3 (continued )
Characteristics
All patients with grade 3þ GU toxicity
Patients with grade 3þ GU toxicities without
pretreatment TURP*
Univariate Multivariate Univariate Multivariate
P-value HR (CI) P-value HR (CI) P-value HR (CI) P-value HR (CI)
V70 .0007 0.4 (0.3-0.7) .4834 1.7 (0.4-6.6) .0065 0.4 (0.2-0.8) .7954 1.8 (0.4-7.4)
V75 .0006 0.4 (0.3-0.7) .9696 0.6 (0.4-1.3) .0023 0.4 (0.2-0.7) .5155 0.6 (0.2-2.0)
V80 .0192 0.6 (0.3-0.9) NT - .1244 0.6 (0.3-1.1) NT -
V82 .1785 1.6 (0.8-3.2) NT - .1398 1.8 (0.9-4.5) NT -
% Bladder volume (cm3)
V30 .0047 0.5 (0.3-0.8) NT - .0059 0.4 (0.2-0.8) NT -
V39 .0082 0.5 (0.3-0.8) NT - .0118 0.4 (0.2-0.8) NT -
V70 .0069 0.5 (0.3-0.8) NT - .0104 0.4 (0.2-0.8) NT -
V75 .0046 0.5 (0.3-0.8) NT - .0079 0.4 (0.2-0.8) NT -
V80 .0063 0.5 (0.3-0.8) NT - .0040 0.4 (0.2-0.8) NT -
V82 .2302 1.5 (0.8-3.0) NT - .1712 1.8 (0.8-4.3) NT -
% Bladder wall volume
(cm3)
V30 .0043 0.5 (0.3-0.8) NT - .0688 0.6 (0.3-1.1) NT -
V39 .0032 0.5 (0.3-0.8) NT - .0935 0.6 (0.3-1.1) NT -
V70 .0015 0.5 (0.3-0.8) NT - .0471 0.5 (0.3-1.0) NT -
V75 .0028 0.5 (0.3-0.8) NT - .0298 0.5 (0.3-1.0) NT -
V80 .0088 0.5 (0.3-0.9) NT - .0091 0.4 (0.2-0.9) NT -
V82 .2202 1.5 (0.8-3.1) NT - .1651 1.8 (0.8-4.3) NT -
Abbreviations: CIZ confidence interval; GUZ genitourinary; HRZ hazard ratio; NAZ not applicable; NTZ not tested in multivariate analysis;
TURP Z transurethral resection of the prostate.
* Includes transurethral resection of the prostate and other prostate reductive procedure.
y Includes a-blockers, a-reductase inhibitors, and pretreatment TURP.
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required TURP for a grade 3 urinary obstruction, including
20 for obstructive symptoms alone and 2 for either hema-
turia or incontinence associated with obstruction. Treat-
ments for hematuria included blood transfusions (nZ5),
HBO (nZ14), cauterization (nZ11), catheterization
(nZ6), and TURP (nZ1), with some patients requiring
more than 1 treatment. Pain syndromes in 3 patients were
treated with HBO (nZ2) and catheterization (nZ1). Two
patients had a transurethral resection or biopsy specimen
showing necrotic bladder tissue. The single grade 4 event
was hematuria, which occurred in a patient living out of the
country; no details regarding precipitating events and
management decisions could be obtained. He had a 6-week
hospitalization with multiple interventions, including blood
transfusions, cauterizations, HBO, and catheterizations
before the hematuria resolved.Factors associated with grade 3D GU toxicity
Univariate analyses of clinical and treatment factors
potentially associated with late CTCAEv3 grade 3þ GU
toxicities in all patients and in the subset of patients who
did not have a pretreatment TURP are shown in Table 3. In
the overall group, significant associations were found be-
tween late CTCAEv3 grade 3þ toxicities and the following
variables: ADT (PZ.0243), prescription anticoagulants
(PZ.0316), prostate volume <40 cm3 versus 40-59 cm3versus 60 cm3 (P<.0001), pretreatment use of a-blockers
(P<.0001), diabetes (PZ.0210), pretreatment TURP
(P<.0001), any pretreatment urologic symptom manage-
ment (P<.0001), and several doseevolume histogram
(DVH) parameters for relative and absolute volumes of
bladder and bladder wall exposed to various dose levels. In
a univariate analysis restricted to patients without pre-
treatment TURP, factors significantly associated with
CTCAEv3 grade 3þ toxicity included prostate volume
<40 cm3 versus 40-59 cm3 versus 60 cm3 (P<.0001),
ablockers (P<.0001), any pretreatment urologic symptom
management (PZ.0019), diabetes (PZ.0447), and bladder
DVH parameters.Multivariate analyses for GU toxicity
Multivariate analyses were performed in both the overall
group and the group without pretreatment TURP to deter-
mine which factors were most predictive of late CTCAEv3
grade 3þ toxicity (Tables 3 and 4). Factors contributing to a
predictive model for all grade 3þ events included pre-
treatment TURP, prostate volume, pretreatment a-blockers,
and DVH parameters. As shown in Table 4, patients with no
risk factors and 1, 2, and 3 or more risk factors had a 1.9%,
3.6%, 11.3%, and 17.8% estimated risk of grade
3þ toxicity at 5 years, respectively (P<.0001). In patients
who did not have a pretreatment TURP, significant pre-
dictors for toxicity were prostate volume, pretreatment a-
Table 4 Factors associated with late grade 3þ genitourinary
toxicity on multivariate analyses
No. of risk
factors
Total with grade
3þ toxicity/no. of
patients
5-year estimates of
freedom from grade
3+ toxicity
0 14/720 (1.9%) 1.9%
1 13/355 (3.7%) 3.6%
2 26/174 (14.9%) 11.3%
3 or 4 8/40 (20.0%) 17.8%
Factors tested in this multivariate analysis included prostate volume,
anticoagulation, pretreatment cytoreductive prostate procedures, pre-
treatment treatment with a-blockers, International Prostate Symptom
Score, and 8 dose-volume histogram (DVH) parameters.
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30 Gy(RBE), and diabetes.
As shown in Table 5, patients in whom grade 3þ toxicity
developed had a larger median prostate volume, more
frequent pretreatment use of a-blockers, a higher incidence
of pretreatment TURP, and a higher volume of bladder
tissue receiving a dose of 30 Gy(RBE) than did the overall
study group.Impact of conversion from CTCAEv3 to CTCAEv4
When patient toxicities were retrospectively reassessed
according to CTCAEv4, some grade 3þ events were
downgraded. The overall and late actuarial 5-year grade
3þ GU toxicity rates changed from 5.4% and 4.7% with
CTCAEv3 to 3.0% and 2.9% with CTCAEv4.Late GI toxicity
Late CTCAEv3and v4 grade 3 GI symptoms occurred in 9
patients. Grade 3 events included 1 case of diarrhea, 7 cases
of rectal bleeding requiring transfusion, and 1 case of rectal
ulceration, which occurred after an endoscopic biopsy of
inflamed rectal mucosa that required temporary colostomy
for healing. The 5-year actuarial incidence of late grade 3
GI toxicity was 0.6%.Table 5 Factors associated with late grade 3þ genitourinary toxicit
Factors No
Prostate volume 60 cm3 38/1097 (3.5%)
a-blockers 37/1044 (3.5%)
Pretreatment TURP* 44/1193 (3.7%)
Absolute bladder
V30  19.2 cm3
34/989 (3.4%)
Abbreviation: TURP Z transurethral resection of the prostate.
Factors tested in this multivariate analysis included prostate volume, antico
treatment with a-blockers, International Prostate Symptom Score, and 8 dose-
* Includes all prostate-reductive procedures.Patient-reported outcomes
As shown in Table 6, at 5 years of follow-up, the median
baseline International Prostate Symptom Score remained
unchanged at 7. Similarly, the median and mean EPIC
summary scores for bowel, urinary irritative/obstructive,
and urinary incontinence domains remained relatively sta-
ble. When mean differences were tested, only sexual
function summary scores for patients not using ADT
significantly declined from baseline to 5 years according to
the minimal significant change test (15). Between baseline
and 5 years, the mean scores in patients not receiving ADT
declined from 67 to 53, and median sexual summary scores
fell from 75 to 55.
Clinical trial versus outcome tracking protocol
patients
A comparison of the patients enrolled on the clinical trials
and those only on the OTP is provided in Tables E1 and E2
(available online at www.redjournal.org). Patients treated
only on the OTP were less likely to receive radiation doses
over 80 Gy(RBE) to the prostate and less likely to receive
elective seminal vesicle radiation doses over 60 Gy(RBE)
than were patients included in the clinical trials. Patients
only on the OTP were also more likely to have >50% of
positive results from zones undergoing biopsy than were
patients treated on the clinical trials. Still, the multivariate
analysis shown in Table E3 (available online at www.
redjournal.org) examining risk factors for recurrence in
the intermediate-risk patient population among the OTP
patients failed to show a relationship between total dose,
elective seminal vesicle radiation dose, or percentage of
positive cancer results from zones undergoing biopsy and
biochemical control at 5 years.
Discussion
This study represents the largest published series to date
documenting the efficacy of dose-escalated PT for localized
prostate cancer with prospectively collected patient-
reported QOL and toxicity data. All patients were treated
at a single institution with conventionally fractionatedy on multivariate analyses
Yes P-value
23/188 (12.2%) <.0001
24/245 (9.8%) .0002
17/96 (17.7%) <.0001
27/298 (9.1%) .0002
agulation, pretreatment cytoreductive prostate procedures, pretreatment
volume histogram (DVH) parameters.
Table 6 EPIC patient-reported quality of life
Factor
Baseline 4 years 5 years 6þ years
No. of
patients
Median
(range)
Mean
(SD)
No. of
patients
Median
(range)
Mean
(SD)
No. of
patients
Median
(range)
Mean
(SD)
No. of
patients
Median
(range)
Mean
(SD)
IPSS 1167 7 (0-34) - 727 7 (0-30) - 505 7 (0-34) - 264 6 (0-35) -
Urinary/obstructive
summary
1122 88 (44-100) 87 (12) 701 93.75 (25-100) 89 (12) 575 94 (19-100) 88 (14) 373 94 (0-100) 89 (14)
Urinary
incontinence
summary
1139 100 (31-100) 95 (16) 704 100 (23-100) 89 (16) 582 100 (0-100) 90 (16) 371 100 (0-100) 89 (18)
Bowel summary 1158 100 (33-100) 87 (9) 715 95 (29-100) 91 (13) 589 96 (21-100) 92 (13) 381 96 (0-100) 92 (14)
Sexual summary
without ADT
962 75 (0-75) 67 (29) 610 53 (0-100) 51 (32) 502 55 (0-100) 53 (33) 337 49 (0-100) 47 (33)
Sexual summary
with ADT
169 17 (0-100) 34 (32) 81 26 (0-100) 41 (33) 69 32 (0-100) 37 (30) 34 26 (0-88) 37 (27)
Abbreviations: ADTZ androgen deprivation therapy; EPICZ Expanded Prostate Cancer Index Composite; IPSSZ International Prostate Symptom
Score; SD Z standard deviation.
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5.5 years. The primary goal of the study was to determine
whether the results of our first 3 benchmark prospective
trials (7) using standard-dose fractionation could be repli-
cated in a larger population of men treated in a similar
fashion. In the benchmark clinical trials, the 5-year FFBP
rates were 99% for low-risk, 99% for intermediate-risk, and
76% for high-risk prostate cancer. In the current larger
study, the 5-year FFBR rates are the similar for low-risk
and high-risk disease but slightly lower for intermediate-
risk disease (94% vs 99%). The reason for the difference
is unclear but may relate to a larger, broader sample of
patients in the present study. A comparison of the patients
enrolled on the benchmark prospective protocols and the
remaining OTP patients is provided in Tables E1 and E2Table 7 Literature review
Study
No. of
patients Therapy
Median RT
Gy or CG
Mendenhall et al (7) 211 Proton therapy 78-82
Slater et al, 2004 (6) 1255 Proton therapy 74
Spratt et al, 2013 (16) 1002 IMRT 86.4
Vora et al, 2013 (17) 302 IMRT 75.6
Liauw et al, 2009 (18) 130 IMRT 76
Pugh et al, 2013 (19) 291 Proton therapy 76
Present study, 2015 1215 Proton therapy 78
Abbreviations: BCRZ biochemical control rate; CGEZ cobalt-Gray equiva
Z high risk; IMRT Z intensity modulated radiation therapy; IR Z intermedi
* 7-year results.
y 9-year results.(available online at www.redjournal.org). Although differ-
ences between the 2 groups of patients were seen with re-
gard to disease characteristics and treatment, the
differences did not appear to be significant predictors for
biochemical failure on multivariate analysis. Consequently,
the reasons for the small decline in biochemical control in
the intermediate-risk patient population remains unclear.Tumor control comparison with IMRT
Our study shows that PT is a highly effective treatment for
low-risk, intermediate-risk, and high-risk prostate cancer.
As Table 7 shows, PT provided comparable biochemical
control rates to IMRT (6, 7, 16-19). For example, Sprattdose
E
Median
F/U years
5-year
BCR (%)
G3þ GI
toxicity
G3þ GU
toxicity
5.2 LR, 99%
IR, 99%
HR, 76%
0.5% 1.0%
5.3 73% 1% 1%
5.5 LR, 98.8%*
IR, 85.6%*
HR, 67.9%*
0.7% 2.2%
7.6 LR, 77.4%y
IR, 69.6%y
HR, 53.3%y
0% 0.7%
4.4 LR, 97%
IR, 94%
HR, 87%
2% 2%
2.0 -
-
-
<0.3% 0%
5.5 LR, 99%
IR, 94%
HR, 74%
0.6% 2.9%
lent; F/UZ follow-up; GIZ gastrointestinal; GUZ genitourinary; HR
ate risk; LR Z low risk.
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men with localized prostate cancer treated with high-dose
IMRT at Memorial Sloan-Kettering Cancer Center, New
York, NY, between 1997 and 2008. The median dose
delivered to the prostate was 86.4 Gy, and the 7-year
biochemical relapse-free survival rate was 98.8% for low-
risk, 85.6% for intermediate-risk, and 67.9% for high-risk
patients (16). Additionally, a series of patients treated
with high-dose photon radiation from the Mayo Clinic,
Phoenix, AZ, showed somewhat lower rates of freedom
from biochemical progression (17). Patients were treated to
a median dose of 75.6 Gy, and 35.4% of patients received
ADT. The median follow-up time was 7.6 years, and the 9-
year freedom from biochemical relapse rates were 77.4%
for low-risk, 69.6% for intermediate-risk, and 53.3% for
high-risk prostate cancer. Although these 3 studies were
stratified by risk category, risk category accounts for only
some of the currently known prognostic factors for patients
with prostate cancer (20). Consequently, our series may not
be directly comparable with the other 2 series. A prospec-
tive comparative study, either randomized or large enough
to account for the effects of heterogeneity, would be
necessary to determine whether PT and IMRT provide
equivalent biochemical control in localized prostate cancer.Toxicity and quality of life compared with IMRT
According to CTCAEv4, the late grade 3þ GU and GI
actuarial toxicity rates at 5 years in this study were 2.9%
and 0.6%, respectively, which is similar to those in other
retrospective series evaluating high-dose IMRT and 3-
dimensional conformal radiation (3DCRT). As Table 7
shows, the risk of grade 3þ GU or GI toxicity is gener-
ally less than 3% after PT and IMRT (16). No prospective
trials comparing toxicity and QOL rates between IMRT
and PT have been reported thus far, but a few retrospec-
tive comparisons have been published. A comparative
study by Gray et al (21) evaluating 3-dimensional
conformal photon radiation (3DCRT), IMRT, and PT re-
ported worse acute patient-reported QOL in the urinary
irritative/obstruction and incontinence domains with
3DCRT and IMRT compared with PT but no differences
between the 3 radiation modalities at 2 years. Hoppe et al
(22) compared prospectively collected patient-reported
QOL data for patients treated with PT for localized
prostate cancer. The 2-year posttreatment results were
compared with patient-reported QOL from the Prostate
Cancer Outcomes and Satisfaction (PROSTQA) treatment
assessment study, which included men with prostate
cancer treated with high-dose photon radiation. At
2 years, there were no differences between treatment
groups in terms of EPIC bowel summary, urinary irrita-
tive, urinary obstructive, or sexual summary scores. When
confounding factors were considered, a statistically sig-
nificant difference between modalities was found: patients
treated with IMRT had more “moderate” or “bigproblems” with rectal urgency and bowel frequency than
those treated with PT. Fang et al (23) published a case-
matched study performed at the University of Pennsyl-
vania comparing physician-reported toxicity for patients
treated with IMRT or PT for prostate cancer. Patients in
the study were retrospectively matched on the basis of
age, prior GU and GI comorbidities, and risk group. At
2 years, there was no significant difference in physician-
reported grade 2þ GU or GI toxicity between IMRT and
PT. Finally, Yu et al (24) published a Medicare-based
comparative study including patients treated with PT or
IMRT for prostate cancer. Toxicities were compared be-
tween the 2 groups, and there was no significant differ-
ence in GI toxicity at 6 or 12 months. The risk for GU
toxicity was significantly lower among patients treated
with PT at 6 months compared with IMRT, but the dif-
ference disappeared by 12 months.
In each comparative study, the follow-up times were
short. Also, patient-reported QOL data were not provided in
the study from the University of Pennsylvania, and the
authors did not report differences in bowel frequency,
diarrhea, or erectile dysfunction between the 2 treatment
groups. This is important because the benefits of PT over
IMRT in reducing dose to the bladder, rectum, and penile
bulb fall within the moderate-dose range of radiation (30-
60 Gy) rather than the high-dose range (70-80 Gy) (23).
The dosimetric improvements in the moderate-dose range
with PT might be expected to result in less erectile
dysfunction, diarrhea, and bowel urgency but not less rectal
bleeding, urethritis, or urethral stricture (22). Additionally,
some side effects, like long-term changes in bowel and
bladder function and second malignancies, require longer
observation times to enable the relative benefit of PT to be
determined. Finally, the Yu et al (24) Medicare-based
study’s lack of treatment-related information (eg, radia-
tion dose, field size), lack of toxicity grading, and reliance
on the presence of codes to detect a toxicity limits the
strength of its conclusions. Large prospective clinical
comparative effectiveness studies with longer follow-up
times will be necessary to clarify whether PT reduces the
risk for side effects compared with IMRT, brachytherapy,
stereotactic body radiation therapy or a combination of
these treatments.Study limitations and strengths
Our study has several limitations, including the potential
for selection bias related to clinical factors and access to
care. The patients who chose to be treated with PT may not
have been directly comparable with patients who received
IMRT, brachytherapy, or surgery in terms of risk factors for
recurrence or toxicity after treatment. Although we are
confident that PT was delivered in a consistent manner,
ADT was provided heterogeneously and for varying dura-
tions, potentially obfuscating the impact of ADT on our
population. Third, our reported local control rates may be
Bryant et al. International Journal of Radiation Oncology  Biology  Physics434overestimates because a biopsy of the prostate was
commonly not performed unless isolated local failure was
suspected.
The strengths of this analysis are its large cohort size,
short accrual times, and consistent patient treatment at a
single institution with consistent guidelines for radiation
delivery, follow-up, and toxicity management. Another
important strength is the simultaneous and prospective
assessment of outcomes such as disease control, patient-
reported QOL, and physician-reported toxicity assessment.
It is concluded that image guided PT provides excellent
biochemical control rates for patients with low-risk, inter-
mediate-risk, and high-risk prostate cancer. The actuarial
rates of CTCAEv4 grade 3þ GU and GI toxicity rates were
low. Significant correlations were found between urologic
toxicity and pretreatment use of a-blockers, diabetes,
TURP, prostate volume, and volume of bladder receiving
30 Gy(RBE), with the risk of toxicity increasing with an
increase in the number of predictive factors. From pre-
treatment to 5 years of follow-up, a significant decline was
found in mean EPIC sexual summary for patients not
receiving ADT. Prospective comparative studies are needed
for a definitive comparison of PT with IMRT.References
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